Restoring Biological Harmony for Patients with Debilitating Disease 1 miRagen Therapeutics NASDAQ: MGEN Jefferies Virtual Healthcare Conference June 2 – June 4, 2020 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements relating to Miragen Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic candidates, our planned clinical trials, the timing of and our ability to obtain and maintain regulat ...

Miragen Therapeutics, Inc. (MGEN) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Dan Ferry - Managing Director of LifeSci Advisors Bill Marshall - President & Chief Executive Officer Jason Leverone - Chief Financial Officer Conference Call Participants Liana Moussatos - Wedbush Securities Leland Gershell - Oppenheimer Jonathan Miller - Evercore ISI Operator Greetings and welcome to the Miragen Therapeutics First Quarter 2020 Earnings Conference Call. At this time, all participa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 MIRAGEN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-K ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 _____________________________________ ...

miRagen Therapeutics, Inc. (MGEN) Q4 2019 Earnings Conference Call March 11, 2020 4:30 PM ET Company Participants Dan Ferry - Managing Director of LifeSci Advisors Bill Marshall - President and CEO Diana Escolar - Chief Medical Officer Jason Leverone - CFO Conference Call Participants Kambiz Yazdi - Wedbush Securities Jonathan Miller - Evercore ISI Operator Greetings. Welcome to miRagen Therapeutics Fourth Quarter 2019 Earnings Call. [Operator Instructions] Please note this conference is being recorded. I w ...

miRagen Therapeutics, Inc. (MGEN) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants Dan Ferry – Managing Director of LifeSci Advisors Bill Marshall – President and Chief Executive Officer Jason Leverone – Chief Financial Officer Conference Call Participants Jonathan Miller – Evercore ISI Leland Gershell – Oppenheimer Madhu Kumar – R.W. Baird Liana Moussatos – Wedbush Securities Operator Thank you for standing by. This is the conference operator. Welcome to the miRagen Therape ...

Table of Contents or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File No. 001-36483 FORM 10-Q MIRAGEN THERAPEUTICS, INC. (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 (Exact name of registrant as specified in its charter) Delaware (State or ot ...

miRagen Therapeutics, Inc. (MGEN) Q2 2019 Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors, LLC Bill Marshall – President and Chief Executive Officer Jason Leverone – Chief Financial Officer Conference Call Participants Liana Moussatos – Wedbush Securities Jonathan Miller – Evercore ISI Jennifer Grayson – R. W. Baird Leland Gershell – Oppenheimer Suji Jeong – Jefferies Operator Greetings and welcome to the miRagen Therapeutics’ Q2 2019 Ea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 MIRAGEN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j ...

Restoring Biological Harmony for Patients with Debilitating Disease Pg. 1 miRagen Therapeutics NASDAQ: MGEN Jefferies 2019 Healthcare Conference June 2019 Cautionary Note Regarding Forward-Looking Statements Pg. 2 This presentation contains forward-looking statements relating to Miragen Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic candidates, our planned clinical trials, the timing of and our ability to obtain and maintain regulatory a ...